- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars | 2 | Benzinga.com | ||
| 08.01. | Enliven Therapeutics meldet positive Phase-1b-Daten für CML-Medikament ELVN-001 | 9 | Investing.com Deutsch | ||
| 08.01. | Enliven reports positive initial phase 1b data for ELVN-001 in CML | 2 | Investing.com | ||
| 08.01. | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | 143 | PR Newswire | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| 07.01. | Enliven Therapeutics beruft Scott Garland vor entscheidender CML-Studie in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 07.01. | Scott Garland joins Enliven Therapeutics board as company prepares for CML trial | 1 | Investing.com | ||
| 07.01. | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | Enliven Therapeutics appoints Rick Fair as new CEO | 1 | Investing.com | ||
| 11.12.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces New CEO to Drive Next Phase of Development | 202 | PR Newswire | Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer
Co-Founder Sam... ► Artikel lesen | |
| 11.12.25 | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 194 | PR Newswire | Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML
Remains on track to initiate Phase 3 pivotal trial of ELVN-001... ► Artikel lesen | |
| 12.11.25 | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.08.25 | Enliven Therapeutics, Inc Q2 Loss Climbs | 1 | RTTNews | ||
| 13.08.25 | Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04 | 2 | Seeking Alpha | ||
| 13.08.25 | Enliven Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | 353 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| 13.06.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 498 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 14.05.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 651 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
| 14.05.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 783 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,894 | -0,36 % | EILMELDUNG: Valneva rutscht ab - kippt die Stimmung jetzt? - nicht verpassen! | ||
| BIOFRONTERA | 2,440 | 0,00 % | BIOFRONTERA AG - Stabilität als strategisches Signal | ||
| CRISPR THERAPEUTICS | 42,000 | -0,47 % | Citizens senkt Kursziel für CRISPR Therapeutics auf 80 US-Dollar, bleibt aber optimistisch | ||
| DENALI THERAPEUTICS | 18,090 | -1,42 % | Denali präsentiert auf dem WORLDSymposium klinische Daten zu Therapien für seltene Krankheiten | ||
| FATE THERAPEUTICS | 0,956 | -4,40 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| AGIOS | 23,000 | 0,00 % | Agios Pharmaceuticals, Inc.: U.S. FDA Approves Agios' AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia | AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name in the U.S. for thalassemia... ► Artikel lesen | |
| UNIQURE | 19,020 | -0,73 % | What Analysts Are Saying About uniQure Stock | ||
| CELLECTIS | 3,240 | +0,93 % | Cellectis Announces 2026 Strategy and Catalysts | NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,272 | -0,67 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 20,000 | -3,33 % | TECX, GKOS, GH, ALGN, NMRA Surge After Hours On Clinical Data And Earnings | WASHINGTON (dpa-AFX) - Several healthcare and life sciences names posted notable gains in after-hours trading, driven by clinical updates, earnings releases, and in some cases, unexplained momentum.Tectonic... ► Artikel lesen | |
| SCILEX | 8,520 | +0,06 % | Scilex invests $20 million in medical tech firm Quantum Scan | ||
| ALLOGENE THERAPEUTICS | 1,835 | +15,41 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T | 1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with... ► Artikel lesen | |
| NUVATION BIO | 5,245 | -1,69 % | Truist Securities raises Nuvation Bio stock price target to $13 on Ibtrozi uptake | ||
| QIAGEN | 44,620 | +0,64 % | Adidas schmiert ab, Qiagen zieht an: DAX-Ausblick | Der DAX hat eine volatile Woche hinter sich. Unter dem Strich büßte das größte deutsche Börsenbarometer knapp 400 Punkte ein und schloss -1,57% tiefer mit 24.900 Punkten. Die höchsten Verluste gab es... ► Artikel lesen |
Das Unternehmen ENLIVEN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,12 % bei einem Aktienkurs von 26,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.